Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 391-395

  Arai, T ^a   Watanabe, J ^a   Kawaguchi, M ^a   Kamata, Y ^a   Nishimura, Y ^a   Jobo, T ^a   Kuramoto, H ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Carcinogenesis; Cell cycle; Clear cell adenocarcinoma of endometrium; E cadherin; Immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; CYCLIN A; CYCLIN D1; CYCLIN E; GLYCOPROTEIN P; KI 67 ANTIGEN; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; UVOMORULIN;

ADENOCARCINOMA; ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CARCINOGENESIS; CLEAR CELL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOCARCINOMA, CLEAR CELL; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CADHERINS; CARCINOMA, ENDOMETRIOID; COHORT STUDIES; CYCLIN A; CYCLIN D1; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645336303     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00494.x     Document Type: Article

References (28)

1. Carcangin ML Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium. Int J Gynecol Pathol 1995 14 30 8.
2. Hoskins WJ Perze CA Young RC. Gynecologic oncology 2nd edn. Philadelphia Lippincott-Raven 1997 31 60.
3. Abeler VM Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathologic and clinical study of 97 cases. Gynecol Oncol 1991 40 207 17.
4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983 15 10 7.
5. Sherman ME Bur ME Kurman RJ et al. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995 26 1268 74.
6. Kohler MF Berchuck A Davidoff AM et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992 52 1622 7.
7. Lax SF Pizer ES Ronnett BM et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen and progesterone receptor expression. Hum Pathol 1998 29 551 8.
8. FIGO news. Corpus cancer staging. Int J Gynaecol Obstet 1989 28 189 93.
9. Fujisawa T Watanabe J Akaboshi M et al. Immunohistochemical study on VEGF expression in endometrial carcinoma - comparison with p53 expression, angiogenesis, and tumor histologic grade. J Cancer Res Clin Oncol 2001 127 668 74.
10. Akaboshi M Watanabe J Fujisawa T et al. Immunohistochemical expression of cdk2 and Ki-67 in human endometrial carcinoma. J Jpn Soc Clin Cytol 2001 40 121 7.
11. Kyushima N Watanabe J Hata H et al. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol 2002 128 307 12.
12. Kato N Watanabe J Jobo T et al. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma and its clinicopathological significance. J Cancer Res Clin Oncol 2003 129 222 6.
13. Nishimura Y Watanabe J Jobo T et al. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. Anticancer Res 2004 24 2185 91.
14. Miyamoto T Watanabe J Hata H et al. Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. J Steroid Biochem Mol Biol 2004 92 3 111 8.
15. Rosenberg P Wingren S Simonsen E et al. Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer. Gynecol Oncol 1989 35 50 4.
16. Holcomb K Delatorre R Pedemonte B et al. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 2002 100 1290 5.
17. Vang R Whitaker BP Farhood AI et al. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001 20 252 9.
18. Vang R Barner R Wheeler DT et al. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial arias-stella reaction from high-grade carcinoma, including clear cell carcinoma. Int J Gynecol Pathol 2004 23 223 33.
19. Bradshaw DM Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998 16 3674 90.
20. Hamada H. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A 1986 83 7785 9.
21. Thibodeau SN Bren G Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993 260 816 9.
22. Ikeda K Sakai K Yamamoto R et al. Multivariate analysis for prognostic significance of histologic subtype, GST-Pi, MDR-1, and p53 in stage II-IV ovarian cancer. Int J Gynecol Cancer 2003 13 776 84.
23. Schneider J Efferth T Mattern CJ et al. High rate of expression of multidrug resistance associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue. Eur J Cancer 1993 29 554 8.
24. Itamochi H Kigawa J Sugiyama T et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002 100 281 7.
25. Burks RT Kessis TD Cho KR et al. Microsatellite instability in endometrial carcinoma. Oncogene 1994 9 1163 6.
26. Risinger JI Berchuck A Kohler MF et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993 53 5100 3.
27. Cai KQ Albarracin C Rosen D et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 2000 35 552 9.
28. Staebler A Lax SF Ellenson LH et al. Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with microsatellite instability. Hum Pathol 2000 31 354 8.